早期非小细胞肺癌患者的生存及生活质量结局：真实世界证据的文献综述
Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.
作者信息
Jovanoski Nick, Bowes Kathleen, Brown Audrey, Belleli Rossella, Di Maio Danilo, Chadda Shkun, Abogunrin Seye
机构信息
F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Building 002/OG18, CH-4070, Basel, Switzerland.
Genesis Research, West One, Forth Banks, Newcastle, NE1 3PA, UK.
出版信息
Lung Cancer Manag. 2023 Jul 12;12(3):LMT60. doi: 10.2217/lmt-2023-0003. eCollection 2023 Sep.
Abstract
AIM
Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients.
METHODS
Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies.
RESULTS
Disease-free proportion decreased in stage III vs stage I patients. Recurrence-free proportion decreased with age and disease stage. Advanced stage and vascular invasion increased risk of late recurrence. Conditional 5-year relative survival rates did not exceed 87%, indicating higher mortality in eNSCLC survivors. Lower conditional survival rates and relative survival rates were associated with older age and advanced disease. Survivors of eNSCLC had poorer physical quality-of-life.
CONCLUSION
Despite curative-intent therapy, survivors of eNSCLC still face significant risks of recurrence, excess mortality, and diminished quality-of-life.
摘要
目的
评估早期非小细胞肺癌（eNSCLC）患者的长期生存情况和生活质量结局。
方法
回顾观察性研究中eNSCLC患者接受根治性治疗后的长期生存情况和生活质量。
结果
与I期患者相比，III期患者的无病比例下降。无复发比例随年龄和疾病分期的增加而下降。晚期和血管侵犯会增加晚期复发风险。5年条件相对生存率不超过87%，表明eNSCLC幸存者的死亡率较高。较低的条件生存率和相对生存率与高龄和疾病进展有关。eNSCLC幸存者的身体生活质量较差。
结论
尽管进行了根治性治疗，eNSCLC幸存者仍面临着复发、额外死亡和生活质量下降的重大风险。
相似文献
1
Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.早期非小细胞肺癌患者的生存及生活质量结局：真实世界证据的文献综述
Lung Cancer Manag. 2023 Jul 12;12(3):LMT60. doi: 10.2217/lmt-2023-0003. eCollection 2023 Sep.
2
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
3
Aspects of survival from colorectal cancer in Denmark.丹麦结直肠癌的生存情况
Dan Med J. 2012 Apr;59(4):B4428.
4
Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence.早期非小细胞肺癌局部区域复发患者的治疗模式和生存：真实世界证据的文献回顾。
Med Oncol. 2022 Oct 29;40(1):4. doi: 10.1007/s12032-022-01790-0.
5
Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.早期非小细胞肺癌患者术后循环肿瘤DNA检测的预后价值：一项系统评价和荟萃分析
Ther Adv Med Oncol. 2023 May 27;15:17588359231177008. doi: 10.1177/17588359231177008. eCollection 2023.
6
Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021.2011 - 2021年美国早期非小细胞肺癌患者的真实世界生物标志物检测应用及后续治疗
Oncol Ther. 2023 Sep;11(3):343-360. doi: 10.1007/s40487-023-00234-7. Epub 2023 Jun 18.
8
Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival.手术治疗肺癌患者的条件生存：总生存、无复发生存和相对生存的综合分析。
Cancer Res Treat. 2021 Oct;53(4):1057-1071. doi: 10.4143/crt.2020.1308. Epub 2021 Mar 9.
9
Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States.用阿替利珠单抗估计美国早期非小细胞肺癌的复发预防和成本避免。
Cancer Med. 2023 Mar;12(6):7450-7458. doi: 10.1002/cam4.5462. Epub 2022 Nov 24.
10
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
引用本文的文献
1
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with + NSCLC.生活质量在非小细胞肺癌（NSCLC）患者日常功能、与医护团队沟通及治疗决策中的作用
JTO Clin Res Rep. 2025 Jun 13;6(9):100863. doi: 10.1016/j.jtocrr.2025.100863. eCollection 2025 Sep.
2
Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study.在瑞士使用抗PD-(L)1药物治疗早期癌症对健康的影响：一项建模研究。
Front Immunol. 2025 Jul 3;16:1601377. doi: 10.3389/fimmu.2025.1601377. eCollection 2025.
3
Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada.加拿大可切除的ALK阳性非小细胞肺癌患者辅助使用阿来替尼与化疗的成本效益
Pharmacoeconomics. 2025 Apr 23. doi: 10.1007/s40273-025-01488-x.
4
The value of peripheral blood inflammation markers in risk assessment and prediction of lung cancer.外周血炎症标志物在肺癌风险评估和预测中的价值。
Future Sci OA. 2025 Dec;11(1):2476870. doi: 10.1080/20565623.2025.2476870. Epub 2025 Mar 13.
5
The links between symptom burden, illness perception, psychological resilience, social support, coping modes, and cancer-related worry in Chinese early-stage lung cancer patients after surgery: a cross-sectional study.中国早期肺癌术后患者症状负担、疾病认知、心理弹性、社会支持、应对方式与癌因性担忧的关系：一项横断面研究。
BMC Psychol. 2024 Aug 31;12(1):463. doi: 10.1186/s40359-024-01946-9.
6
Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的基因特征及治疗策略进展
Front Med (Lausanne). 2024 Feb 27;11:1326426. doi: 10.3389/fmed.2024.1326426. eCollection 2024.
本文引用的文献
1
Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival.手术治疗肺癌患者的条件生存：总生存、无复发生存和相对生存的综合分析。
Cancer Res Treat. 2021 Oct;53(4):1057-1071. doi: 10.4143/crt.2020.1308. Epub 2021 Mar 9.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.电视辅助胸腔镜肺叶切除术治疗临床N1期非小细胞肺癌的长期疗效：与开胸手术的倾向评分加权比较
Lung Cancer. 2020 Dec;150:201-208. doi: 10.1016/j.lungcan.2020.10.014. Epub 2020 Oct 29.
4
Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.完全切除的非小细胞肺癌接受改良周疗nab-紫杉醇联合卡铂辅助化疗的生存结果：FAST-nab 研究。
Anticancer Drugs. 2020 Feb;31(2):177-182. doi: 10.1097/CAD.0000000000000857.
5
Long-Term Oncologic Outcomes After Robotic Lobectomy for Early-stage Non-Small-cell Lung Cancer Versus Video-assisted Thoracoscopic and Open Thoracotomy Approach.机器人肺叶切除术与电视辅助胸腔镜手术和开胸手术治疗早期非小细胞肺癌的长期肿瘤学结果比较。
Clin Lung Cancer. 2020 May;21(3):214-224.e2. doi: 10.1016/j.cllc.2019.10.004. Epub 2019 Oct 13.
6
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.非小细胞肺癌：流行病学、筛查、诊断和治疗。
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
7
Long-Term Prognosis After Segmentectomy for cT1 N0 M0 Non-Small Cell Lung Cancer.cT1N0M0 期非小细胞肺癌行解剖性肺段切除术的长期预后。
Ann Thorac Surg. 2019 May;107(5):1500-1506. doi: 10.1016/j.athoracsur.2018.11.046. Epub 2018 Dec 21.
8
Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.非小细胞肺癌幸存者的生活质量：一项多中心横断面研究。
J Thorac Oncol. 2019 Mar;14(3):420-435. doi: 10.1016/j.jtho.2018.11.019. Epub 2018 Nov 30.
9
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
10
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.新辅助或辅助化疗治疗 cT2-4N0-1 期非小细胞肺癌的结果：倾向评分匹配分析。
J Thorac Cardiovasc Surg. 2019 Feb;157(2):743-753.e3. doi: 10.1016/j.jtcvs.2018.09.098. Epub 2018 Oct 10.
Zotero 插件